The dependence of the Yersinia pestis capsule on pathogenesis is influenced by the mouse background

Eric H Weening1, Jason S Cathelyn, Greer Kaufman

  • 1Department of Genetics, University of North Carolina, Chapel Hill, North Carolina, USA.

Infection and Immunity
|December 1, 2010
PubMed

Insights

Yersinia pestis requires both PsaA and Caf1 fimbriae for full virulence in plague models. Deleting these genes significantly reduces bacterial burden and increases lethal dose, highlighting their importance as vaccine targets.

Area of Science:

  • Microbiology
  • Immunology
  • Pathogenesis

Background:

  • Yersinia pestis causes plague, a devastating epidemic disease.
  • Understanding Y. pestis virulence factors is crucial for developing effective vaccines.
  • Usher-chaperone fimbriae Psa and Caf are promising vaccine candidates.

Purpose of the Study:

  • To investigate the nonredundant roles of PsaA and Caf1 in Y. pestis pathogenesis.
  • To evaluate the impact of PsaA and Caf1 on virulence in different plague models.
  • To assess the influence of host genetic background on the requirement for these virulence factors.

Main Methods:

  • Construction and characterization of Y. pestis mutant strains lacking psaA and caf1.
  • Assessment of virulence through organ bacterial burden and lethal dose (LD₅₀) determination in C57BL/6J and BALB/cJ mice.
  • Subcutaneous infection models for bubonic and pneumonic plague.

Main Results:

  • Deletion of psaA decreased organ bacterial burden and increased LD₅₀ in C57BL/6J mice.
  • Deletion of caf1 significantly decreased organ bacterial burden and substantially increased LD₅₀.
  • The attenuation of the caf1 deletion mutant was less pronounced in BALB/cJ mice compared to C57BL/6J mice, indicating host-dependent virulence.

Conclusions:

  • Both PsaA and Caf1 are essential, nonredundant virulence factors for Y. pestis.
  • The differential requirement for Caf1 across mouse backgrounds suggests distinct host-pathogen interactions.
  • These findings support PsaA and Caf1 as critical targets for plague vaccine development.